2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-,
905, YM,
quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate,
solifenacin,
solifenacin succinate,
Succinate, Solifenacin,
vesicare,
YM 905,
YM905,
Solifenacin succinate,
242478-38-2,
Vesicare,
Solifenacin (Succinate),
Solifenacin,
Vesikur,
UNII-KKA5DLD701,
YM 905,
Solifenacin succinate [USAN],
KKA5DLD701,
YM905,
YM-905,
1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid,
YM-67905,
CHEMBL1200803,
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid,
2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1),
Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1),
Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1),
Vesicare OD,
Vesicare (TN),
AK160479,
solifenacin-succinate,
AC1Q5VRD,
Solifenacin Succinate Salt,
MLS006010416,
SCHEMBL109333,
AC1L50Q6,
CHEBI:32151,
CTK8G3169,
RXZMMZZRUPYENV-VROPFNGYSA-N,
HY-A0002,
MFCD09952287,
s3048,
AKOS015994745,
AM84825,
CS-0371,
KS-1286,
SB17428,
Solifenacin succinate (JAN/USAN/INN),
YM67905,
Solifenacin succinate, >=98% (HPLC),
AN-15595,
AS-35288,
BC677662,
SMR004701445,
YM-53705,
AB0139087,
AX8032830,
LS-183550,
FT-0657634,
S0944,
ST24049293,
SW219141-1,
KS-00000656,
D01269,
W-5423,
A819262,
Solifenacin succinate, EuropePharmacopoeia (EP) Reference Standard,
Solifenacin Succinate, United States Pharmacopeia (USP) Reference Standard,
Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate,
Solifenacin for system suitability, EuropePharmacopoeia (EP) Reference Standard,
(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate succinate,
(1S)-3,4-Dihydro-1-phenyl-d5-2(1H)-isoquinolinecarboxylic Acid (3R)-1-Azabicyclo-[2.2.2]oct-3-yl Ester Hydrochloride,
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid,
[(3R)-quinuclidin-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; succinic acid,
1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid (Solifenacin?Succinate),
butanedioic acid; (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester,
Succinate, Solifenacin,
Solifenacin-d5 Hydrochloride,
AR-1L5425,
CID216457,
905, YM,
ACN-032226,
CS-O-10001,
B1614,
C23-H26-N2-O2.C4-H6-O4,
C441209,
D000069464,
27958-77-6,
Solifenacin succinate, 98%, a muscarinic receptor antagonist - 1G 1g,
quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate,
2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-,
242478-37-1,
Butanedioic acid, compd. with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1),